In fact, genomic features, such as PD-L1 expression, tumor mutation burden (TMB), neoantigen load, and defects in DNA damage repair, have been associated with tumor immunotherapeutic responsiveness in ovarian cancer (Ghisoni et al., 2019; Odunsi, 2017; Tian et al., 2020). The gene discussed is CD274; the disease is ovarian carcinoma.